GlassScriptPhysician profile
Eric J Biondo Savin
NPI 1043530215
$1,053.18
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.39 · 2022: $284 · 2023: $386 · 2024: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $205.62 | 2022-2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $165.24 | 2022-2024 | Ajovy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $84.45 | 2022-2023 | Gammagard |
| Lilly USA, LLC | $79.24 | 2023-2024 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $69.36 | 2022-2024 | |
| Amgen INC. | $55.50 | 2024 | Uplizna |
| Ucb, INC. | $53.47 | 2022-2023 | Briviact |
| Biogen, INC. | $50.63 | 2023-2024 | Spinraza |
| Eisai INC. | $50.28 | 2024 | |
| Jazz Pharmaceuticals INC. | $42.26 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.44 | 2022 | |
| Genzyme Corporation | $22.24 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2024 | Keveyis |
| Acadia Pharmaceuticals INC | $17.70 | 2024 | Nuplazid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $16.29 | 2022 | |
| Csl Behring | $15.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.02 | 2023 | Nuedexta |
| Travere Therapeutics, INC. | $10.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Biondo Savin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.